APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Hemocompatible Coatings

Hemocompatible coatings constitute advanced interfacial modifications applied to the surfaces of blood-contacting medical devices to mitigate the risk of thrombosis and associated complications. These coatings function by attenuating the initial adsorption of plasma proteins, particularly fibrinogen and von Willebrand factor, thereby suppressing subsequent platelet adhesion, activation, and aggregation, as well as inhibiting activation of the intrinsic coagulation pathway. Effective hemocompatibility is achieved through precise control of surface chemistry and topography, addressing the fundamental challenge that virtually all synthetic biomaterials elicit a thrombogenic response upon blood exposure unless appropriately engineered.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Hemocompatible coatings constitute advanced interfacial modifications applied to the surfaces of blood-contacting medical devices to mitigate the risk of thrombosis and associated complications. These coatings function by attenuating the initial adsorption of plasma proteins, particularly fibrinogen and von Willebrand factor, thereby suppressing subsequent platelet adhesion, activation, and aggregation, as well as inhibiting activation of the intrinsic coagulation pathway. Effective hemocompatibility is achieved through precise control of surface chemistry and topography, addressing the fundamental challenge that virtually all synthetic biomaterials elicit a thrombogenic response upon blood exposure unless appropriately engineered.

Classification of hemocompatible coatings is based primarily on mechanism: active bioactive coatings versus passive bioinert coatings. Active coatings utilize covalently immobilized anticoagulants, with endpoint-attached heparin being the predominant example; the preserved antithrombin-binding pentasaccharide sequence catalyzes the inhibition of thrombin and factor Xa at the device surface without elution of the heparin molecule. Passive coatings rely on biomimetic or highly hydrophilic polymers, notably phosphorylcholine-based methacrylates, which replicate the zwitterionic character of the outer leaflet of endothelial cell membranes to form a stable hydration shell. This layer exerts steric repulsion and charge neutrality to minimize nonspecific protein fouling and cellular interactions independent of any pharmacological activity.

Deposition methods encompass covalent photoimmobilization, endpoint chemical coupling, plasma polymerization, and solution-based coating techniques, each optimized for substrate compatibility and mechanical durability under physiological shear stress. These technologies are integrated into a broad spectrum of devices, encompassing coronary and peripheral endovascular stents, ePTFE and polyester vascular grafts, indwelling catheters for central venous access and hemodialysis, extracorporeal membrane oxygenation circuits and cardiopulmonary bypass components, and rotary blood pumps in ventricular assist systems. Validation through ISO 10993-4 hemocompatibility testing protocols, complemented by ex vivo flow loop studies, large-animal implantation models, and clinical performance data from regulatory-approved devices, substantiates the reduction in thrombus formation and improvement in device patency and safety.

Selected research

Market Outlook & Growth Opportunities

Global Hemocompatible Coatings Market Outlook and Growth Opportunities 2026

Report ID 17444638053 August 2026199 pages

Choose your research edition.

Industry ResearchHemocompatible Coatings Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemocompatible Coatings Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Hemocompatible Coatings Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemocompatible Coatings Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemocompatible Coatings Market Analysis and Forecast 2026-2032177 pages · $4,950 USD

Market perspective

Hemocompatible coatings constitute advanced interfacial modifications applied to the surfaces of blood-contacting medical devices to mitigate the risk of thrombosis and associated complications. These coatings function by attenuating the initial adsorption of plasma proteins, particularly fibrinogen and von Willebrand factor, thereby suppressing subsequent platelet adhesion, activation, and aggregation, as well as inhibiting activation of the intrinsic coagulation pathway. Effective hemocompatibility is achieved through precise control of surface chemistry and topography, addressing the fundamental challenge that virtually all synthetic biomaterials elicit a thrombogenic response upon blood exposure unless appropriately engineered.

Classification of hemocompatible coatings is based primarily on mechanism: active bioactive coatings versus passive bioinert coatings. Active coatings utilize covalently immobilized anticoagulants, with endpoint-attached heparin being the predominant example; the preserved antithrombin-binding pentasaccharide sequence catalyzes the inhibition of thrombin and factor Xa at the device surface without elution of the heparin molecule. Passive coatings rely on biomimetic or highly hydrophilic polymers, notably phosphorylcholine-based methacrylates, which replicate the zwitterionic character of the outer leaflet of endothelial cell membranes to form a stable hydration shell. This layer exerts steric repulsion and charge neutrality to minimize nonspecific protein fouling and cellular interactions independent of any pharmacological activity.

Deposition methods encompass covalent photoimmobilization, endpoint chemical coupling, plasma polymerization, and solution-based coating techniques, each optimized for substrate compatibility and mechanical durability under physiological shear stress. These technologies are integrated into a broad spectrum of devices, encompassing coronary and peripheral endovascular stents, ePTFE and polyester vascular grafts, indwelling catheters for central venous access and hemodialysis, extracorporeal membrane oxygenation circuits and cardiopulmonary bypass components, and rotary blood pumps in ventricular assist systems. Validation through ISO 10993-4 hemocompatibility testing protocols, complemented by ex vivo flow loop studies, large-animal implantation models, and clinical performance data from regulatory-approved devices, substantiates the reduction in thrombus formation and improvement in device patency and safety.

Read the full market overview

The global Hemocompatible Coatings market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hemocompatible Coatings is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hemocompatible Coatings is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for Hemocompatible Coatings is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hemocompatible Coatings market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hemocompatible Coatings market include Surmodics, Carmeda AB, Coatings2Go, DSM Biomedical, Hydromer, AST Products, Smart Reactors, Alfa Chemistry and Biomerics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Hemocompatible Coatings market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hemocompatible Coatings and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hemocompatible Coatings revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Hemocompatible Coatings market.

Hemocompatible Coatings Segment by Company

Surmodics

Carmeda AB

Coatings2Go

DSM Biomedical

Hydromer

AST Products

Smart Reactors

Alfa Chemistry

Biomerics

Jiangsu Biosurf Biotech

Corline Biomedical

BioInteractions

Aurorium

Alta Biomed

jMedtech

Hemocompatible Coatings Segment by Type

Active (heparin)

Passive (non-heparin)

Hemocompatible Coatings Segment by Application

Interventional Catheters

ECMO & Extracorporeal

Stents & Vascular Grafts

Hemocompatible Coatings Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hemocompatible Coatings status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Hemocompatible Coatings key companies, revenue, market share, and recent developments.

3. To split the Hemocompatible Coatings breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Hemocompatible Coatings market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hemocompatible Coatings significant trends, drivers, influence factors in global and regions.

6. To analyze Hemocompatible Coatings competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemocompatible Coatings market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemocompatible Coatings and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemocompatible Coatings.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hemocompatible Coatings industry.

Chapter 3: Detailed analysis of Hemocompatible Coatings company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Hemocompatible Coatings in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Hemocompatible Coatings in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hemocompatible Coatings Industry Trends Table 2. Hemocompatible Coatings Industry Drivers Table 3. Hemocompatible Coatings Industry Opportunities and Challenges Table 4. Hemocompatible Coatings Industry Restraints Table 5. Global Hemocompatible Coatings Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hemocompatible Coatings Revenue Share by Company (2021-2026) Table 7. Global Hemocompatible Coatings Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Hemocompatible Coatings Key Company Manufacturing Base & Headquarters Table 9. Global Hemocompatible Coatings Company, Product Type & Application Table 10. Global Hemocompatible Coatings Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Hemocompatible Coatings by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Active (heparin) Table 15. Significant Companies of Passive (non-heparin) Table 16. Global Hemocompatible Coatings Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Hemocompatible Coatings Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Hemocompatible Coatings Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Hemocompatible Coatings Sales Value Share by Type (2021-2026) Table 20. Global Hemocompatible Coatings Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Interventional Catheters Table 22. Significant Companies of ECMO & Extracorporeal Table 23. Significant Companies of Stents & Vascular Grafts Table 24. Global Hemocompatible Coatings Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hemocompatible Coatings Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Hemocompatible Coatings Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Hemocompatible Coatings Sales Value Share by Application (2021-2026) Table 28. Global Hemocompatible Coatings Sales Value Share by Application (2027-2032) Table 29. Global Hemocompatible Coatings Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Hemocompatible Coatings Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Hemocompatible Coatings Sales Value Share by Region (2021-2026) Table 32. Global Hemocompatible Coatings Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Hemocompatible Coatings Sales Value Share by Region (2027-2032) Table 34. Global Hemocompatible Coatings Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Hemocompatible Coatings Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Hemocompatible Coatings Sales Value Market Share by Country (2021-2026) Table 37. Global Hemocompatible Coatings Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Hemocompatible Coatings Sales Value Market Share by Country (2027-2032) Table 39. Surmodics Company Information Table 40. Surmodics Business Overview Table 41. Surmodics Hemocompatible Coatings Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Surmodics Hemocompatible Coatings Product Portfolio Table 43. Surmodics Recent Development Table 44. Carmeda AB Company Information Table 45. Carmeda AB Business Overview Table 46. Carmeda AB Hemocompatible Coatings Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Carmeda AB Hemocompatible Coatings Product Portfolio Table 48. Carmeda AB Recent Development Table 49. Coatings2Go Company Information Table 50. Coatings2Go Business Overview Table 51. Coatings2Go Hemocompatible Coatings Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Coatings2Go Hemocompatible Coatings Product Portfolio Table 53. Coatings2Go Recent Development Table 54. DSM Biomedical Company Information Table 55. DSM Biomedical Business Overview Table 56. DSM Biomedical Hemocompatible Coatings Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. DSM Biomedical Hemocompatible Coatings Product Portfolio Table 58. DSM Biomedical Recent Development Table 59. Hydromer Company Information Table 60. Hydromer Business Overview Table 61. Hydromer Hemocompatible Coatings Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Hydromer Hemocompatible Coatings Product Portfolio Table 63. Hydromer Recent Development Table 64. AST Products Company Information Table 65. AST Products Business Overview Table 66. AST Products Hemocompatible Coatings Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. AST Products Hemocompatible Coatings Product Portfolio Table 68. AST Products Recent Development Table 69. Smart Reactors Company Information Table 70. Smart Reactors Business Overview Table 71. Smart Reactors Hemocompatible Coatings Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Smart Reactors Hemocompatible Coatings Product Portfolio Table 73. Smart Reactors Recent Development Table 74. Alfa Chemistry Company Information Table 75. Alfa Chemistry Business Overview Table 76. Alfa Chemistry Hemocompatible Coatings Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Alfa Chemistry Hemocompatible Coatings Product Portfolio Table 78. Alfa Chemistry Recent Development Table 79. Biomerics Company Information Table 80. Biomerics Business Overview Table 81. Biomerics Hemocompatible Coatings Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Biomerics Hemocompatible Coatings Product Portfolio Table 83. Biomerics Recent Development Table 84. Jiangsu Biosurf Biotech Company Information Table 85. Jiangsu Biosurf Biotech Business Overview Table 86. Jiangsu Biosurf Biotech Hemocompatible Coatings Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Jiangsu Biosurf Biotech Hemocompatible Coatings Product Portfolio Table 88. Jiangsu Biosurf Biotech Recent Development Table 89. Corline Biomedical Company Information Table 90. Corline Biomedical Business Overview Table 91. Corline Biomedical Hemocompatible Coatings Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Corline Biomedical Hemocompatible Coatings Product Portfolio Table 93. Corline Biomedical Recent Development Table 94. BioInteractions Company Information Table 95. BioInteractions Business Overview Table 96. BioInteractions Hemocompatible Coatings Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. BioInteractions Hemocompatible Coatings Product Portfolio Table 98. BioInteractions Recent Development Table 99. Aurorium Company Information Table 100. Aurorium Business Overview Table 101. Aurorium Hemocompatible Coatings Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Aurorium Hemocompatible Coatings Product Portfolio Table 103. Aurorium Recent Development Table 104. Alta Biomed Company Information Table 105. Alta Biomed Business Overview Table 106. Alta Biomed Hemocompatible Coatings Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 107. Alta Biomed Hemocompatible Coatings Product Portfolio Table 108. Alta Biomed Recent Development Table 109. jMedtech Company Information Table 110. jMedtech Business Overview Table 111. jMedtech Hemocompatible Coatings Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 112. jMedtech Hemocompatible Coatings Product Portfolio Table 113. jMedtech Recent Development Table 114. Research Programs/Design for This Report Table 115. Authors List of This Report Table 116. Secondary Sources Table 117. Primary Sources List of Figures Figure 1. Hemocompatible Coatings Product Image Figure 2. Global Hemocompatible Coatings Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemocompatible Coatings Market Size (2021-2032) & (US$ Million) Figure 4. Global Hemocompatible Coatings Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Active (heparin) Image Figure 8. Passive (non-heparin) Image Figure 9. Global Hemocompatible Coatings Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Hemocompatible Coatings Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Hemocompatible Coatings Sales Value Share by Type (2021-2032) Figure 12. Interventional Catheters Image Figure 13. ECMO & Extracorporeal Image Figure 14. Stents & Vascular Grafts Image Figure 15. Global Hemocompatible Coatings Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Hemocompatible Coatings Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Hemocompatible Coatings Sales Value Share by Application (2021-2032) Figure 18. Global Hemocompatible Coatings Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Hemocompatible Coatings Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Hemocompatible Coatings Sales Value (2021-2032) & (US$ Million) Figure 21. North America Hemocompatible Coatings Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Hemocompatible Coatings Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Hemocompatible Coatings Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Hemocompatible Coatings Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Hemocompatible Coatings Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Hemocompatible Coatings Sales Value (2021-2032) & (US$ Million) Figure 27. South America Hemocompatible Coatings Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Hemocompatible Coatings Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Hemocompatible Coatings Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Hemocompatible Coatings Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Active (heparin)
  • Passive (non-heparin)
Applications
  • Interventional Catheters
  • ECMO & Extracorporeal
  • Stents & Vascular Grafts
Companies covered
  • Surmodics
  • Carmeda AB
  • Coatings2Go
  • DSM Biomedical
  • Hydromer
  • AST Products
  • Smart Reactors
  • Alfa Chemistry
  • Biomerics
  • Jiangsu Biosurf Biotech
  • Corline Biomedical
  • BioInteractions
  • Aurorium
  • Alta Biomed
  • jMedtech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hemocompatible Coatings Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hemocompatible Coatings Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Hemocompatible Coatings Market Dynamics
  1. 2.1 Hemocompatible Coatings Industry Trends
  2. 2.2 Hemocompatible Coatings Industry Drivers
  3. 2.3 Hemocompatible Coatings Industry Opportunities and Challenges
  4. 2.4 Hemocompatible Coatings Industry Restraints
3 Hemocompatible Coatings Market by Company
  1. 3.1 Global Hemocompatible Coatings Company Revenue Ranking in 2025
  2. 3.2 Global Hemocompatible Coatings Revenue by Company (2021-2026)
  3. 3.3 Global Hemocompatible Coatings Company Ranking (2024-2026)
  4. 3.4 Global Hemocompatible Coatings Company Manufacturing Base and Headquarters
  5. 3.5 Global Hemocompatible Coatings Company Product Type and Application
  6. 3.6 Global Hemocompatible Coatings Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Hemocompatible Coatings Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Hemocompatible Coatings Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Hemocompatible Coatings Market by Type
  1. 4.1 Hemocompatible Coatings Type Introduction
  2. 4.1.1 Active (heparin)
  3. 4.1.2 Passive (non-heparin)
  4. 4.2 Global Hemocompatible Coatings Sales Value by Type
  5. 4.2.1 Global Hemocompatible Coatings Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hemocompatible Coatings Sales Value by Type (2021-2032)
  7. 4.2.3 Global Hemocompatible Coatings Sales Value Share by Type (2021-2032)
5 Hemocompatible Coatings Market by Application
  1. 5.1 Hemocompatible Coatings Application Introduction
  2. 5.1.1 Interventional Catheters
  3. 5.1.2 ECMO & Extracorporeal
  4. 5.1.3 Stents & Vascular Grafts
  5. 5.2 Global Hemocompatible Coatings Sales Value by Application
  6. 5.2.1 Global Hemocompatible Coatings Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hemocompatible Coatings Sales Value by Application (2021-2032)
  8. 5.2.3 Global Hemocompatible Coatings Sales Value Share by Application (2021-2032)
6 Hemocompatible Coatings Regional Value Analysis
  1. 6.1 Global Hemocompatible Coatings Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hemocompatible Coatings Sales Value by Region (2021-2032)
  3. 6.2.1 Global Hemocompatible Coatings Sales Value by Region: 2021-2026
  4. 6.2.2 Global Hemocompatible Coatings Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hemocompatible Coatings Sales Value (2021-2032)
  7. 6.3.2 North America Hemocompatible Coatings Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Hemocompatible Coatings Sales Value (2021-2032)
  10. 6.4.2 Europe Hemocompatible Coatings Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Hemocompatible Coatings Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Hemocompatible Coatings Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Hemocompatible Coatings Sales Value (2021-2032)
  16. 6.6.2 South America Hemocompatible Coatings Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Hemocompatible Coatings Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Hemocompatible Coatings Sales Value Share by Country, 2025 VS 2032
7 Hemocompatible Coatings Country-level Value Analysis
  1. 7.1 Global Hemocompatible Coatings Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hemocompatible Coatings Sales Value by Country (2021-2032)
  3. 7.2.1 Global Hemocompatible Coatings Sales Value by Country (2021-2026)
  4. 7.2.2 Global Hemocompatible Coatings Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Hemocompatible Coatings Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Hemocompatible Coatings Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Hemocompatible Coatings Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Surmodics
  2. 8.1.1 Surmodics Company Information
  3. 8.1.2 Surmodics Business Overview
  4. 8.1.3 Surmodics Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Surmodics Hemocompatible Coatings Product Portfolio
  6. 8.1.5 Surmodics Recent Developments
  7. 8.2 Carmeda AB
  8. 8.2.1 Carmeda AB Company Information
  9. 8.2.2 Carmeda AB Business Overview
  10. 8.2.3 Carmeda AB Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Carmeda AB Hemocompatible Coatings Product Portfolio
  12. 8.2.5 Carmeda AB Recent Developments
  13. 8.3 Coatings2Go
  14. 8.3.1 Coatings2Go Company Information
  15. 8.3.2 Coatings2Go Business Overview
  16. 8.3.3 Coatings2Go Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Coatings2Go Hemocompatible Coatings Product Portfolio
  18. 8.3.5 Coatings2Go Recent Developments
  19. 8.4 DSM Biomedical
  20. 8.4.1 DSM Biomedical Company Information
  21. 8.4.2 DSM Biomedical Business Overview
  22. 8.4.3 DSM Biomedical Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  23. 8.4.4 DSM Biomedical Hemocompatible Coatings Product Portfolio
  24. 8.4.5 DSM Biomedical Recent Developments
  25. 8.5 Hydromer
  26. 8.5.1 Hydromer Company Information
  27. 8.5.2 Hydromer Business Overview
  28. 8.5.3 Hydromer Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hydromer Hemocompatible Coatings Product Portfolio
  30. 8.5.5 Hydromer Recent Developments
  31. 8.6 AST Products
  32. 8.6.1 AST Products Company Information
  33. 8.6.2 AST Products Business Overview
  34. 8.6.3 AST Products Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AST Products Hemocompatible Coatings Product Portfolio
  36. 8.6.5 AST Products Recent Developments
  37. 8.7 Smart Reactors
  38. 8.7.1 Smart Reactors Company Information
  39. 8.7.2 Smart Reactors Business Overview
  40. 8.7.3 Smart Reactors Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Smart Reactors Hemocompatible Coatings Product Portfolio
  42. 8.7.5 Smart Reactors Recent Developments
  43. 8.8 Alfa Chemistry
  44. 8.8.1 Alfa Chemistry Company Information
  45. 8.8.2 Alfa Chemistry Business Overview
  46. 8.8.3 Alfa Chemistry Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Alfa Chemistry Hemocompatible Coatings Product Portfolio
  48. 8.8.5 Alfa Chemistry Recent Developments
  49. 8.9 Biomerics
  50. 8.9.1 Biomerics Company Information
  51. 8.9.2 Biomerics Business Overview
  52. 8.9.3 Biomerics Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Biomerics Hemocompatible Coatings Product Portfolio
  54. 8.9.5 Biomerics Recent Developments
  55. 8.10 Jiangsu Biosurf Biotech
  56. 8.10.1 Jiangsu Biosurf Biotech Company Information
  57. 8.10.2 Jiangsu Biosurf Biotech Business Overview
  58. 8.10.3 Jiangsu Biosurf Biotech Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Jiangsu Biosurf Biotech Hemocompatible Coatings Product Portfolio
  60. 8.10.5 Jiangsu Biosurf Biotech Recent Developments
  61. 8.11 Corline Biomedical
  62. 8.11.1 Corline Biomedical Company Information
  63. 8.11.2 Corline Biomedical Business Overview
  64. 8.11.3 Corline Biomedical Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Corline Biomedical Hemocompatible Coatings Product Portfolio
  66. 8.11.5 Corline Biomedical Recent Developments
  67. 8.12 BioInteractions
  68. 8.12.1 BioInteractions Company Information
  69. 8.12.2 BioInteractions Business Overview
  70. 8.12.3 BioInteractions Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  71. 8.12.4 BioInteractions Hemocompatible Coatings Product Portfolio
  72. 8.12.5 BioInteractions Recent Developments
  73. 8.13 Aurorium
  74. 8.13.1 Aurorium Company Information
  75. 8.13.2 Aurorium Business Overview
  76. 8.13.3 Aurorium Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Aurorium Hemocompatible Coatings Product Portfolio
  78. 8.13.5 Aurorium Recent Developments
  79. 8.14 Alta Biomed
  80. 8.14.1 Alta Biomed Company Information
  81. 8.14.2 Alta Biomed Business Overview
  82. 8.14.3 Alta Biomed Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Alta Biomed Hemocompatible Coatings Product Portfolio
  84. 8.14.5 Alta Biomed Recent Developments
  85. 8.15 jMedtech
  86. 8.15.1 jMedtech Company Information
  87. 8.15.2 jMedtech Business Overview
  88. 8.15.3 jMedtech Hemocompatible Coatings Revenue and Gross Margin (2021-2026)
  89. 8.15.4 jMedtech Hemocompatible Coatings Product Portfolio
  90. 8.15.5 jMedtech Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst